NEW YORK, Aug. 1, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2024.To join the MacroGenics class action, go to https://rosenlega ...

RADNOR, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland against MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) on behalf of investors who purchased MacroGenics stock or sold MacroGenics puts between March 7, 2024 to May 9, 2024, inclusive (the “Class Period”) The lead plaintiff deadline is September 24, 2024. CONTA ...

NEW ORLEANS, July 31, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 24, 2024 to file lead plaintiff applications in a securities class action lawsuit against MacroGenics, Inc. (or the “Company”) (NasdaqGS: MGNX), if they purchased the Company’s shares or sold the Company’s puts between March 7, 2024 to May 9, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Mar ...

MacroGenics Inc. MGNX announced on Tuesday that it reviewed data accumulated from the TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo).In May, when the company released interim data from the trial, MacroGenics reported five deaths (fatal outcome) during the trial.After reviewing, MacroGenics agreed with the study’s Independent Data Monitoring Committee’s recommendation to discontinue the treatment for the remaining metastatic castration-resistant prostate cancer (mCRPC) study participants who ...

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ: MGNX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MacroGenics investors who were adversely affected by alleged securities fraud between March 7, 2024 and May 9, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/macrogenics-inc-lawsuit- ...

Macrogenics (NASDAQ:MGNX) stock is dropping on Wednesday as the biopharmaceutical company prepares to discontinue a clinical trial of vobramitamab duocarmazine.This is the company’s candidate for metastatic castration-resistant prostate cancer (mCRPC). The company has decided to no longer move forward with its TAMARACK Phase 2 study for patients who could have received additional doses.Macrogenics is making this decision due to the primary endpoint of its study already being met. This suggestion came from t ...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired MacroGenics, Inc. (NASDAQ: MGNX) common stock between March 7, 2024 and May 9, 2024. MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. For more information, submit a form, email a ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX) in the United States District Court for the District of Maryland on behalf of all persons and entities who purchased or otherwise acquired MacroGenics securities between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”). Investors have ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of stock or sellers of puts of MacroGenics, Inc. (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 24, 2024. SO WHAT: If you purchased stock or sold puts of M ...

Abstract of clinical data accepted for poster presentation at ESMO Congress 2024 in SeptemberESMO poster to include protocol-defined TAMARACK Phase 2 mCRPC study data, including pre-defined landmark primary endpoint of 6-month rPFS rate and updated safetyTreatment recently discontinued for TAMARACK mCRPC study participants who remained eligible for further dosing following review of totality of data, including efficacy, and emerging adverse events associated with prolonged exposure and considering potential ...